Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly \[IM\] preoperatively and 30 mg twice daily \[BID\] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.

NCT Number	NCT06968806
Lead Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Collaborators: Guangdong Provincial People's Hospital, Huai'an First People's Hospital, Shandong Provincial Hospital, First Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital of Harbin Medical University, The First Affilated Hospital of the Medical College, Shihezi University, Xinhua Hospital of Ili Kazak Autonomous Prefecture, Henan Provincial Chest Hospital
Conditions	Aortic Dissection, Inflammation
Enrollment	360 participants
Start Date	2025-10-27
Primary Completion	2027-09-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-23